Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial
Vaccine (2022) - Comments
pubmed: 35501178  doi: 10.1016/j.vaccine.2022.04.035  issn: 0264-410x  issn: 1873-2518 

Taisei Masuda, Kyoko Murakami, Kenkichi Sugiura, Sho Sakui, Ron P Schuring, Mitsuhiro Mori